Want real case studies? 10 seconds to sign up
Join the platform
Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
January 12, 2026
Approximately 5 minutes
Good Distribution Practice for Medicinal Products in the EU – Spanish Implementation by AEMPS
Legal Basis and Scope
Good Distribution Practice (GDP) in Spain is governed by EU Guidelines on Good Distribution Practice of medicinal products for human use (2013/C 343/01), transposed through Royal Decree 782/2013 and aligned with Delegated Regulation (EU) 2016/161 on safety features. AEMPS is the competent authority responsible for authorising, inspecting, and supervising wholesale distribution activities to ensure medicines maintain their quality, safety, and efficacy from manufacturer to dispenser. The guidelines apply to all entities involved in wholesale distribution, storage, and transport of authorised human medicines, including brokers and parallel traders. Industria de distribución de medicamentos – BPD UE - AEMPS
Authorisation Requirements
- Wholesale Distribution Authorisation: Mandatory for any entity storing or distributing medicines at national or EU level; applications submitted to AEMPS include details on premises, quality system, responsible person, and procedures.
- Responsible Person: A qualified person must be designated to ensure GDP compliance and act as the contact point for AEMPS.
- Premises and Equipment: Suitable, secure, clean, and temperature-controlled facilities with validated monitoring systems (e.g., data loggers for cold chain).
- Transport: Qualified carriers and vehicles; risk-based approach for temperature-sensitive products.
Core GDP Principles
- Quality Management: Documented quality system with SOPs, risk assessments, deviation management, and self-inspections.
- Personnel: Trained staff with defined responsibilities; initial and continuous training programmes.
- Documentation: Complete records of receipt, storage, distribution, and returns; traceability of each batch.
- Storage Conditions: Appropriate environmental controls (temperature, humidity, light) with continuous monitoring and alarm systems.
- Complaints, Returns, and Recalls: Procedures for handling complaints, quarantining returns, and executing recalls in coordination with AEMPS.
- Falsified Medicines Prevention: Risk-based controls, verification of suppliers, and reporting of suspected falsified products.
Inspections and Certification
AEMPS conducts routine and for-cause GDP inspections. Satisfactory inspections result in a GDP certificate, valid for 5 years and recognised across the EU/EEA. Non-compliance may lead to improvement notices, suspension, or revocation of authorisation.
Practical Implications for Distributors
Distributors must integrate serialisation verification (scanning DataMatrix codes) and decommissioning via SEVeM, maintain an up-to-date quality system, and prepare for unannounced inspections. AEMPS provides guidance documents, checklists, training resources, and a public register of authorised distributors.
This implementation of EU GDP ensures high standards of medicine distribution in Spain, protecting patients from substandard or falsified products while facilitating legitimate parallel trade and supply chain efficiency. Detailed guidelines, application forms, inspection procedures, and authorised entity information are available on the AEMPS distribution industry page dedicated to EU GDP. Industria de distribución de medicamentos – BPD UE - AEMPS
ElendiLabs Regulatory Affairs Team
100+ products successfully registered across global markets. Get unbeatable quotations and expert answers — fast.
Ask Anything
We'll follow up with you personally.
100% response rate • Reply within 7 business days
Related Articles
Approximately 5 minutes
Pharmaceutical Distribution and Laboratory Authorisations in Spain – AEMPS Requirements
AEMPS regulates pharmaceutical distribution and laboratory activities in Spain, requiring specific authorisations for wholesale distribution, manufacturing laboratories, and control laboratories to ensure traceability, quality, and compliance with Good Distribution Practice (GDP) and Good Manufacturing Practice (GMP) standards across the supply chain.
Approximately 5 minutes
Customs-Controlled and Supervised Medicinal Product Warehouses in Spain – AEMPS Guidelines
AEMPS regulates warehouses under customs control or supervision in Spain for storage of imported medicinal products awaiting customs clearance or release, ensuring compliance with storage conditions, security, traceability, and Good Distribution Practice (GDP) principles to maintain medicine quality and prevent entry of falsified products.
Approximately 5 minutes
Register of Authorised Pharmaceutical Distribution Entities in Spain – AEMPS Catalogue
AEMPS maintains a public catalogue listing all authorised entities involved in pharmaceutical distribution in Spain, including wholesale distributors, manufacturers with distribution activities, import entities, and customs-supervised warehouses, to promote transparency, facilitate verification of legitimacy, and support regulatory compliance across the supply chain.
Approximately 5 minutes
Register of Medicinal Product Intermediaries in Spain – AEMPS Public List
AEMPS maintains a public register of authorised intermediaries in the medicinal product distribution chain in Spain, listing brokers and other entities that negotiate or arrange transactions without holding stock, to ensure transparency, regulatory compliance, and prevention of falsified medicines in line with EU requirements.
Approximately 5 minutes
Verification of Legality of Suppliers and Customers in Pharmaceutical Distribution – AEMPS Guidance
AEMPS requires wholesale distributors in Spain to verify the legitimacy and authorisation status of suppliers and customers before transactions, using the public AEMPS catalogue and other registers, to prevent falsified medicines from entering the legitimate supply chain and ensure compliance with EU Falsified Medicines Directive obligations.